# CyTOF

Type: Technology

Source: SaaS Intelligence Brief — https://getsaasbrief.com/entity/cytof
Canonical HTML page: https://getsaasbrief.com/entity/cytof

## Recent coverage (1 stories)

### Evolent and Standard BioTools Signal Shift to Efficiency in 2025 Results
2026-02-24 22:44:12 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter. Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.
Full story: https://getsaasbrief.com/story/evolent-standard-biotools-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getsaasbrief.com/guides/methodology for the full editorial methodology.